Valeant Pharmaceuticals International entered into an agreement to acquire Xcel Pharmaceuticals. The deal could worth up to US$280 M. Upon acquisition of Xcel, Valeant acquires four neurology products such as Diastat®, Mysoline®, Migranal® and D.H.E. 43®.